Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01957670
(Sponsor decision due to change the clinical indication to Chronic Insomnia)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Main Inclusion Criteria:
Male or female, 18 years of age and over at screening
Diagnosis of mild to moderate Dry Eye, as defined by:
Positive corneal fluorescein staining , defined as a corneal punctate fluorescein staining score of ≥3 in either eye by the National Eye Institute evaluation scale summed over 5 areas, each with a 0-3 scoring scale; AND
Schirmer Test score (with anesthesia, 5 minutes < 5 mm either eye) ; AND
OSDI score of ≥12 and OSDI score of <33
Main Exclusion Criteria:
Persistent intraocular inflammation or infection including conjunctivitis at the time of the study or 2 weeks prior to study start.
Any concomitant active or history of eye disease including, but not limited to lid abnormalities, nasolacrimal obstruction, active ulcer, glaucoma or ocular herpes simplex virus infection
Patients currently using topical steroidal or anti-inflammatory eye drops for 1 month prior to screening
Receipt of any type of topical artificial eye drops within 3 days prior to screening
Receipt of topical cyclosporine eye drops within 3 months prior to screening